Wegovy and period issues: what we know so far

What the trial data and NHS guidance say about periods and semaglutide

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks and reported an average body-weight reduction of around 15% at the 2.4 mg maintenance dose. The trial was not designed to track menstrual outcomes, so no systematic cycle data were collected — which is one reason the evidence base here is thinner than patients often expect. What we can say is that meaningful weight loss reliably shifts the hormonal environment in women of reproductive age, and those shifts have documented downstream effects on the menstrual cycle.

The NHS semaglutide medicines page lists the recognised side effects of Wegovy in detail. Irregular periods do not appear on that list. That absence matters: it means cycle changes are not a pharmacological effect the regulators have attributed directly to semaglutide itself, though they do not rule out an indirect pathway via weight reduction and the hormonal changes that accompany it.

In practice, many women report their first noticeable cycle change within two to three months of starting treatment, which broadly tracks the point at which meaningful weight loss tends to begin. The timing is not coincidental.

How rapid weight loss can disturb the menstrual cycle

Fat tissue is metabolically active. It produces oestrogen and influences the balance of sex hormones that govern ovulation and cycle length. When body weight falls (particularly when it falls quickly) that balance shifts, and the hypothalamic-pituitary-ovarian axis, which orchestrates the monthly cycle, has to recalibrate. The recalibration is not always smooth.

Lighter, irregular, or temporarily absent periods are among the most common results. Some women experience the opposite: heavier or more frequent bleeding, especially if they were previously under-ovulating due to excess adipose tissue suppressing normal hormonal signalling. For women with polycystic ovary syndrome, the picture is more complex. PCOS is strongly associated with obesity, and cycles in PCOS are often irregular or absent because of insulin resistance and elevated androgens. As weight falls and insulin sensitivity improves on semaglutide treatment, ovulation can return, sometimes abruptly and without warning.

That last point carries a practical implication. If periods had been absent or very irregular before treatment, their return does not mean something has gone wrong. It may mean the opposite. It is still worth discussing with a GP, not least because a returning cycle means returning fertility.

Contraception, fertility, and what's different from tirzepatide

A question our prescribers hear regularly: does Wegovy affect how well the pill works? For semaglutide specifically, NHS guidance does not advise adding extra contraception on top of oral contraceptives, because there is no established evidence that semaglutide reduces pill absorption. This stands in contrast to tirzepatide, where the prescribing information does recommend an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, a distinction worth knowing if you are weighing up the two options on the weight-loss treatment overview.

Semaglutide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. The MHRA is clear on this. If a pregnancy is planned, or if a missed period raises that possibility, treatment should be paused and a clinician consulted promptly. The absence of a period on Wegovy is not automatically a sign of pregnancy, but it should not be dismissed either.

For a broader look at how semaglutide interacts with other aspects of reproductive health, the semaglutide side effects and concerns page covers reported experiences in more detail.

When to speak to a GP, and what to keep a note of

Most cycle changes that occur alongside Wegovy treatment settle as the body adjusts to its new weight and hormonal equilibrium. A missed month early in treatment, a slightly shifted cycle length, or a heavier bleed than usual in the first few months are unlikely to be alarming in isolation. That said, there are patterns that need clinical attention.

Speak to a GP if: your period stops entirely for three or more consecutive months; bleeding becomes significantly heavier than your baseline, particularly if it involves clots or lasts longer than seven days; you develop pelvic pain that is new or out of proportion to your usual period discomfort; or a pregnancy is possible and has not been ruled out. These are not reasons to stop treatment without medical advice, but they are reasons to get checked rather than wait.

Keeping a brief note of cycle dates, flow, and any other changes while on treatment is genuinely useful if you do need to discuss this with a clinician. Even noting whether a change coincided with a dose increase can help a prescriber form a clearer picture. If you have questions about how semaglutide treatment is monitored, information on semaglutide and period timing covers that ground. You can also review the full scope of what Wegovy involves as a treatment before making any decision.

The cost of treatment varies by provider; if that is part of your thinking, Wegovy pricing in the UK sets out what influences the figures and what a legitimate private prescription typically includes. When you are ready to talk through whether semaglutide is right for you, speak to our prescribers, a real clinician reads every consultation the same day it is submitted.